<!DOCTYPE html>
<html>
  <script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-79742963-1', 'auto');
  ga('send', 'pageview');

</script>

  <!-- Begin Jekyll SEO tag v2.5.0 -->
<title>What’s new for ‘ACE inhibitors and cancer’ in PubMed | Ciência médica</title>
<meta name="generator" content="Jekyll v3.7.4" />
<meta property="og:title" content="What’s new for ‘ACE inhibitors and cancer’ in PubMed" />
<meta name="author" content="Francisco H C Felix" />
<meta property="og:locale" content="en" />
<meta name="description" content="This message contains My NCBI what’s new results from the National Center for BiotechnologySender’s message: Sent on Saturday, 2011 Sep 24Search angiotensin cancer &lt;div&gt;&lt;div&gt;&lt;table bgcolor=&quot;#CCCCCC&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;5&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap=&quot;nowrap&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Cancer Invest. 2011 Sep 21. [Epub ahead of print]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;PMID: 21936625 [PubMed - as supplied by publisher]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td&gt;&lt;div&gt;&lt;div&gt;&lt;div class=&quot;artAuthors&quot;&gt;Young Kwang Chae,1,2,§ Matias E. Valsecchi,2,3,§ Jongoh Kim,2,4 Anabella Lucca Bianchi,2 Danai Khemasuwan,2,5 Ajit Desai,2 and William Tester,2&lt;div class=&quot;fulltext&quot;&gt;Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,1&lt;/div&gt;&lt;div class=&quot;fulltext&quot;&gt;Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA, USA,2&lt;/div&gt;&lt;div class=&quot;fulltext&quot;&gt;Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA,3&lt;/div&gt;&lt;div class=&quot;fulltext&quot;&gt;Department of Medicine, Balyor College of Medicine, Houston, TX, USA,4&lt;/div&gt;&lt;div class=&quot;fulltext&quot;&gt;Department of Medicine, Cleveland Clinic, Cleveland, OH, USA5&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;NLM_author-notes&quot;&gt;&lt;div class=&quot;first last&quot;&gt;§Both the authors contributed equally to this study.&lt;/div&gt;&lt;div class=&quot;NLM_corresp&quot;&gt;Correspondence to: Young Kwang Chae, MD, MPH, MBA, 1515 Holcombe Blvd, Unit 463, Houston, TX 77030, USA. email: ykchae@mdanderson.org&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;abstractSection&quot;&gt;&lt;div class=&quot;first last&quot;&gt;Background: Epidemiologic and biochemical evidence suggest a role of statins and angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) as anti-neoplastic agents. This study was designed to evaluate the association between the use of these agents and the risk of breast cancer recurrence. Methods: We reviewed the medical records of patients treated for stage II/III breast cancer between 1999 and 2005. Statin and ACE-inhibitors/ARB users were defined as patients who took these medications for at least 6 months in no evidence of disease (NED) stage after the initial diagnosis. The primary outcome was disease-free survival and the secondary was overall survival. The Kaplan–Meier and Cox proportional hazard models were used. Results: A total of 703 patients were included. The median and maximal of follow up was 55 and 118 months, respectively. A total of 168 patients used ACE-inhibitors/ARBs, 156 patients used statins, and 81 used both. Univariate analysis showed significant reduction in breast cancer recurrence among patients who used ACE-inhibitors/ARBs (hazard ratio (HR) = 0.57; 95% CI: 0.37–0.89; p = .013) or statins (HR = 0.43; 95% CI: 0.26–0.70; p &lt; .001). After adjusting for multiple variables, the use of ACE-inhibitors/ARBs (HR = 0.49; 95% CI: 0.31–0.76; p = .002) and statins (HR = 0.40; 95% CI: 0.24–0.67; p &lt; .001) remained significant and an additive effect was found on those who used both drugs (HR = 0.30 95% CI: 0.15–0.61; p = .001). No association was found regarding overall survival. Conclusions: The use of ACE-inhibitors/ARBs, statins, and the combination of both were all associated with a reduced risk of breast cancer recurrence. This observation should prompt further exploration.&lt;/div&gt;&lt;/div&gt;Read More: http://informahealthcare.com/doi/abs/10.3109/07357907.2011.616252&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;" />
<meta property="og:description" content="This message contains My NCBI what’s new results from the National Center for BiotechnologySender’s message: Sent on Saturday, 2011 Sep 24Search angiotensin cancer &lt;div&gt;&lt;div&gt;&lt;table bgcolor=&quot;#CCCCCC&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;5&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap=&quot;nowrap&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Cancer Invest. 2011 Sep 21. [Epub ahead of print]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;PMID: 21936625 [PubMed - as supplied by publisher]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td&gt;&lt;div&gt;&lt;div&gt;&lt;div class=&quot;artAuthors&quot;&gt;Young Kwang Chae,1,2,§ Matias E. Valsecchi,2,3,§ Jongoh Kim,2,4 Anabella Lucca Bianchi,2 Danai Khemasuwan,2,5 Ajit Desai,2 and William Tester,2&lt;div class=&quot;fulltext&quot;&gt;Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,1&lt;/div&gt;&lt;div class=&quot;fulltext&quot;&gt;Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA, USA,2&lt;/div&gt;&lt;div class=&quot;fulltext&quot;&gt;Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA,3&lt;/div&gt;&lt;div class=&quot;fulltext&quot;&gt;Department of Medicine, Balyor College of Medicine, Houston, TX, USA,4&lt;/div&gt;&lt;div class=&quot;fulltext&quot;&gt;Department of Medicine, Cleveland Clinic, Cleveland, OH, USA5&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;NLM_author-notes&quot;&gt;&lt;div class=&quot;first last&quot;&gt;§Both the authors contributed equally to this study.&lt;/div&gt;&lt;div class=&quot;NLM_corresp&quot;&gt;Correspondence to: Young Kwang Chae, MD, MPH, MBA, 1515 Holcombe Blvd, Unit 463, Houston, TX 77030, USA. email: ykchae@mdanderson.org&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;abstractSection&quot;&gt;&lt;div class=&quot;first last&quot;&gt;Background: Epidemiologic and biochemical evidence suggest a role of statins and angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) as anti-neoplastic agents. This study was designed to evaluate the association between the use of these agents and the risk of breast cancer recurrence. Methods: We reviewed the medical records of patients treated for stage II/III breast cancer between 1999 and 2005. Statin and ACE-inhibitors/ARB users were defined as patients who took these medications for at least 6 months in no evidence of disease (NED) stage after the initial diagnosis. The primary outcome was disease-free survival and the secondary was overall survival. The Kaplan–Meier and Cox proportional hazard models were used. Results: A total of 703 patients were included. The median and maximal of follow up was 55 and 118 months, respectively. A total of 168 patients used ACE-inhibitors/ARBs, 156 patients used statins, and 81 used both. Univariate analysis showed significant reduction in breast cancer recurrence among patients who used ACE-inhibitors/ARBs (hazard ratio (HR) = 0.57; 95% CI: 0.37–0.89; p = .013) or statins (HR = 0.43; 95% CI: 0.26–0.70; p &lt; .001). After adjusting for multiple variables, the use of ACE-inhibitors/ARBs (HR = 0.49; 95% CI: 0.31–0.76; p = .002) and statins (HR = 0.40; 95% CI: 0.24–0.67; p &lt; .001) remained significant and an additive effect was found on those who used both drugs (HR = 0.30 95% CI: 0.15–0.61; p = .001). No association was found regarding overall survival. Conclusions: The use of ACE-inhibitors/ARBs, statins, and the combination of both were all associated with a reduced risk of breast cancer recurrence. This observation should prompt further exploration.&lt;/div&gt;&lt;/div&gt;Read More: http://informahealthcare.com/doi/abs/10.3109/07357907.2011.616252&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;" />
<link rel="canonical" href="http://fhcflx.github.io/ciencia-medica/2011/09/24/whats-new-for-ace-inhibitors-and-cancer_24.html" />
<meta property="og:url" content="http://fhcflx.github.io/ciencia-medica/2011/09/24/whats-new-for-ace-inhibitors-and-cancer_24.html" />
<meta property="og:site_name" content="Ciência médica" />
<meta property="og:type" content="article" />
<meta property="article:published_time" content="2011-09-24T09:04:00-03:00" />
<script type="application/ld+json">
{"description":"This message contains My NCBI what’s new results from the National Center for BiotechnologySender’s message: Sent on Saturday, 2011 Sep 24Search angiotensin cancer &lt;div&gt;&lt;div&gt;&lt;table bgcolor=&quot;#CCCCCC&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;5&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap=&quot;nowrap&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Cancer Invest. 2011 Sep 21. [Epub ahead of print]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;PMID: 21936625 [PubMed - as supplied by publisher]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td&gt;&lt;div&gt;&lt;div&gt;&lt;div class=&quot;artAuthors&quot;&gt;Young Kwang Chae,1,2,§ Matias E. Valsecchi,2,3,§ Jongoh Kim,2,4 Anabella Lucca Bianchi,2 Danai Khemasuwan,2,5 Ajit Desai,2 and William Tester,2&lt;div class=&quot;fulltext&quot;&gt;Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,1&lt;/div&gt;&lt;div class=&quot;fulltext&quot;&gt;Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA, USA,2&lt;/div&gt;&lt;div class=&quot;fulltext&quot;&gt;Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA,3&lt;/div&gt;&lt;div class=&quot;fulltext&quot;&gt;Department of Medicine, Balyor College of Medicine, Houston, TX, USA,4&lt;/div&gt;&lt;div class=&quot;fulltext&quot;&gt;Department of Medicine, Cleveland Clinic, Cleveland, OH, USA5&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;NLM_author-notes&quot;&gt;&lt;div class=&quot;first last&quot;&gt;§Both the authors contributed equally to this study.&lt;/div&gt;&lt;div class=&quot;NLM_corresp&quot;&gt;Correspondence to: Young Kwang Chae, MD, MPH, MBA, 1515 Holcombe Blvd, Unit 463, Houston, TX 77030, USA. email: ykchae@mdanderson.org&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;abstractSection&quot;&gt;&lt;div class=&quot;first last&quot;&gt;Background: Epidemiologic and biochemical evidence suggest a role of statins and angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) as anti-neoplastic agents. This study was designed to evaluate the association between the use of these agents and the risk of breast cancer recurrence. Methods: We reviewed the medical records of patients treated for stage II/III breast cancer between 1999 and 2005. Statin and ACE-inhibitors/ARB users were defined as patients who took these medications for at least 6 months in no evidence of disease (NED) stage after the initial diagnosis. The primary outcome was disease-free survival and the secondary was overall survival. The Kaplan–Meier and Cox proportional hazard models were used. Results: A total of 703 patients were included. The median and maximal of follow up was 55 and 118 months, respectively. A total of 168 patients used ACE-inhibitors/ARBs, 156 patients used statins, and 81 used both. Univariate analysis showed significant reduction in breast cancer recurrence among patients who used ACE-inhibitors/ARBs (hazard ratio (HR) = 0.57; 95% CI: 0.37–0.89; p = .013) or statins (HR = 0.43; 95% CI: 0.26–0.70; p &lt; .001). After adjusting for multiple variables, the use of ACE-inhibitors/ARBs (HR = 0.49; 95% CI: 0.31–0.76; p = .002) and statins (HR = 0.40; 95% CI: 0.24–0.67; p &lt; .001) remained significant and an additive effect was found on those who used both drugs (HR = 0.30 95% CI: 0.15–0.61; p = .001). No association was found regarding overall survival. Conclusions: The use of ACE-inhibitors/ARBs, statins, and the combination of both were all associated with a reduced risk of breast cancer recurrence. This observation should prompt further exploration.&lt;/div&gt;&lt;/div&gt;Read More: http://informahealthcare.com/doi/abs/10.3109/07357907.2011.616252&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;","author":{"@type":"Person","name":"Francisco H C Felix"},"@type":"BlogPosting","url":"http://fhcflx.github.io/ciencia-medica/2011/09/24/whats-new-for-ace-inhibitors-and-cancer_24.html","headline":"What’s new for ‘ACE inhibitors and cancer’ in PubMed","dateModified":"2011-09-24T09:04:00-03:00","datePublished":"2011-09-24T09:04:00-03:00","mainEntityOfPage":{"@type":"WebPage","@id":"http://fhcflx.github.io/ciencia-medica/2011/09/24/whats-new-for-ace-inhibitors-and-cancer_24.html"},"@context":"http://schema.org"}</script>
<!-- End Jekyll SEO tag -->

  <head>
  <meta charset="utf-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1">

  <!-- Begin Jekyll SEO tag v2.5.0 -->
<title>What’s new for ‘ACE inhibitors and cancer’ in PubMed | Ciência médica</title>
<meta name="generator" content="Jekyll v3.7.4" />
<meta property="og:title" content="What’s new for ‘ACE inhibitors and cancer’ in PubMed" />
<meta name="author" content="Francisco H C Felix" />
<meta property="og:locale" content="en" />
<meta name="description" content="This message contains My NCBI what’s new results from the National Center for BiotechnologySender’s message: Sent on Saturday, 2011 Sep 24Search angiotensin cancer &lt;div&gt;&lt;div&gt;&lt;table bgcolor=&quot;#CCCCCC&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;5&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap=&quot;nowrap&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Cancer Invest. 2011 Sep 21. [Epub ahead of print]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;PMID: 21936625 [PubMed - as supplied by publisher]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td&gt;&lt;div&gt;&lt;div&gt;&lt;div class=&quot;artAuthors&quot;&gt;Young Kwang Chae,1,2,§ Matias E. Valsecchi,2,3,§ Jongoh Kim,2,4 Anabella Lucca Bianchi,2 Danai Khemasuwan,2,5 Ajit Desai,2 and William Tester,2&lt;div class=&quot;fulltext&quot;&gt;Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,1&lt;/div&gt;&lt;div class=&quot;fulltext&quot;&gt;Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA, USA,2&lt;/div&gt;&lt;div class=&quot;fulltext&quot;&gt;Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA,3&lt;/div&gt;&lt;div class=&quot;fulltext&quot;&gt;Department of Medicine, Balyor College of Medicine, Houston, TX, USA,4&lt;/div&gt;&lt;div class=&quot;fulltext&quot;&gt;Department of Medicine, Cleveland Clinic, Cleveland, OH, USA5&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;NLM_author-notes&quot;&gt;&lt;div class=&quot;first last&quot;&gt;§Both the authors contributed equally to this study.&lt;/div&gt;&lt;div class=&quot;NLM_corresp&quot;&gt;Correspondence to: Young Kwang Chae, MD, MPH, MBA, 1515 Holcombe Blvd, Unit 463, Houston, TX 77030, USA. email: ykchae@mdanderson.org&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;abstractSection&quot;&gt;&lt;div class=&quot;first last&quot;&gt;Background: Epidemiologic and biochemical evidence suggest a role of statins and angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) as anti-neoplastic agents. This study was designed to evaluate the association between the use of these agents and the risk of breast cancer recurrence. Methods: We reviewed the medical records of patients treated for stage II/III breast cancer between 1999 and 2005. Statin and ACE-inhibitors/ARB users were defined as patients who took these medications for at least 6 months in no evidence of disease (NED) stage after the initial diagnosis. The primary outcome was disease-free survival and the secondary was overall survival. The Kaplan–Meier and Cox proportional hazard models were used. Results: A total of 703 patients were included. The median and maximal of follow up was 55 and 118 months, respectively. A total of 168 patients used ACE-inhibitors/ARBs, 156 patients used statins, and 81 used both. Univariate analysis showed significant reduction in breast cancer recurrence among patients who used ACE-inhibitors/ARBs (hazard ratio (HR) = 0.57; 95% CI: 0.37–0.89; p = .013) or statins (HR = 0.43; 95% CI: 0.26–0.70; p &lt; .001). After adjusting for multiple variables, the use of ACE-inhibitors/ARBs (HR = 0.49; 95% CI: 0.31–0.76; p = .002) and statins (HR = 0.40; 95% CI: 0.24–0.67; p &lt; .001) remained significant and an additive effect was found on those who used both drugs (HR = 0.30 95% CI: 0.15–0.61; p = .001). No association was found regarding overall survival. Conclusions: The use of ACE-inhibitors/ARBs, statins, and the combination of both were all associated with a reduced risk of breast cancer recurrence. This observation should prompt further exploration.&lt;/div&gt;&lt;/div&gt;Read More: http://informahealthcare.com/doi/abs/10.3109/07357907.2011.616252&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;" />
<meta property="og:description" content="This message contains My NCBI what’s new results from the National Center for BiotechnologySender’s message: Sent on Saturday, 2011 Sep 24Search angiotensin cancer &lt;div&gt;&lt;div&gt;&lt;table bgcolor=&quot;#CCCCCC&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;5&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap=&quot;nowrap&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Cancer Invest. 2011 Sep 21. [Epub ahead of print]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;PMID: 21936625 [PubMed - as supplied by publisher]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td&gt;&lt;div&gt;&lt;div&gt;&lt;div class=&quot;artAuthors&quot;&gt;Young Kwang Chae,1,2,§ Matias E. Valsecchi,2,3,§ Jongoh Kim,2,4 Anabella Lucca Bianchi,2 Danai Khemasuwan,2,5 Ajit Desai,2 and William Tester,2&lt;div class=&quot;fulltext&quot;&gt;Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,1&lt;/div&gt;&lt;div class=&quot;fulltext&quot;&gt;Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA, USA,2&lt;/div&gt;&lt;div class=&quot;fulltext&quot;&gt;Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA,3&lt;/div&gt;&lt;div class=&quot;fulltext&quot;&gt;Department of Medicine, Balyor College of Medicine, Houston, TX, USA,4&lt;/div&gt;&lt;div class=&quot;fulltext&quot;&gt;Department of Medicine, Cleveland Clinic, Cleveland, OH, USA5&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;NLM_author-notes&quot;&gt;&lt;div class=&quot;first last&quot;&gt;§Both the authors contributed equally to this study.&lt;/div&gt;&lt;div class=&quot;NLM_corresp&quot;&gt;Correspondence to: Young Kwang Chae, MD, MPH, MBA, 1515 Holcombe Blvd, Unit 463, Houston, TX 77030, USA. email: ykchae@mdanderson.org&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;abstractSection&quot;&gt;&lt;div class=&quot;first last&quot;&gt;Background: Epidemiologic and biochemical evidence suggest a role of statins and angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) as anti-neoplastic agents. This study was designed to evaluate the association between the use of these agents and the risk of breast cancer recurrence. Methods: We reviewed the medical records of patients treated for stage II/III breast cancer between 1999 and 2005. Statin and ACE-inhibitors/ARB users were defined as patients who took these medications for at least 6 months in no evidence of disease (NED) stage after the initial diagnosis. The primary outcome was disease-free survival and the secondary was overall survival. The Kaplan–Meier and Cox proportional hazard models were used. Results: A total of 703 patients were included. The median and maximal of follow up was 55 and 118 months, respectively. A total of 168 patients used ACE-inhibitors/ARBs, 156 patients used statins, and 81 used both. Univariate analysis showed significant reduction in breast cancer recurrence among patients who used ACE-inhibitors/ARBs (hazard ratio (HR) = 0.57; 95% CI: 0.37–0.89; p = .013) or statins (HR = 0.43; 95% CI: 0.26–0.70; p &lt; .001). After adjusting for multiple variables, the use of ACE-inhibitors/ARBs (HR = 0.49; 95% CI: 0.31–0.76; p = .002) and statins (HR = 0.40; 95% CI: 0.24–0.67; p &lt; .001) remained significant and an additive effect was found on those who used both drugs (HR = 0.30 95% CI: 0.15–0.61; p = .001). No association was found regarding overall survival. Conclusions: The use of ACE-inhibitors/ARBs, statins, and the combination of both were all associated with a reduced risk of breast cancer recurrence. This observation should prompt further exploration.&lt;/div&gt;&lt;/div&gt;Read More: http://informahealthcare.com/doi/abs/10.3109/07357907.2011.616252&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;" />
<link rel="canonical" href="http://fhcflx.github.io/ciencia-medica/2011/09/24/whats-new-for-ace-inhibitors-and-cancer_24.html" />
<meta property="og:url" content="http://fhcflx.github.io/ciencia-medica/2011/09/24/whats-new-for-ace-inhibitors-and-cancer_24.html" />
<meta property="og:site_name" content="Ciência médica" />
<meta property="og:type" content="article" />
<meta property="article:published_time" content="2011-09-24T09:04:00-03:00" />
<script type="application/ld+json">
{"description":"This message contains My NCBI what’s new results from the National Center for BiotechnologySender’s message: Sent on Saturday, 2011 Sep 24Search angiotensin cancer &lt;div&gt;&lt;div&gt;&lt;table bgcolor=&quot;#CCCCCC&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot;&gt;PubMed Results&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;5&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td nowrap=&quot;nowrap&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Cancer Invest. 2011 Sep 21. [Epub ahead of print]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;PMID: 21936625 [PubMed - as supplied by publisher]&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;10&quot;&gt;&lt;/td&gt;&lt;td&gt;&lt;div&gt;&lt;div&gt;&lt;div class=&quot;artAuthors&quot;&gt;Young Kwang Chae,1,2,§ Matias E. Valsecchi,2,3,§ Jongoh Kim,2,4 Anabella Lucca Bianchi,2 Danai Khemasuwan,2,5 Ajit Desai,2 and William Tester,2&lt;div class=&quot;fulltext&quot;&gt;Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,1&lt;/div&gt;&lt;div class=&quot;fulltext&quot;&gt;Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA, USA,2&lt;/div&gt;&lt;div class=&quot;fulltext&quot;&gt;Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA,3&lt;/div&gt;&lt;div class=&quot;fulltext&quot;&gt;Department of Medicine, Balyor College of Medicine, Houston, TX, USA,4&lt;/div&gt;&lt;div class=&quot;fulltext&quot;&gt;Department of Medicine, Cleveland Clinic, Cleveland, OH, USA5&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;NLM_author-notes&quot;&gt;&lt;div class=&quot;first last&quot;&gt;§Both the authors contributed equally to this study.&lt;/div&gt;&lt;div class=&quot;NLM_corresp&quot;&gt;Correspondence to: Young Kwang Chae, MD, MPH, MBA, 1515 Holcombe Blvd, Unit 463, Houston, TX 77030, USA. email: ykchae@mdanderson.org&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;abstractSection&quot;&gt;&lt;div class=&quot;first last&quot;&gt;Background: Epidemiologic and biochemical evidence suggest a role of statins and angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) as anti-neoplastic agents. This study was designed to evaluate the association between the use of these agents and the risk of breast cancer recurrence. Methods: We reviewed the medical records of patients treated for stage II/III breast cancer between 1999 and 2005. Statin and ACE-inhibitors/ARB users were defined as patients who took these medications for at least 6 months in no evidence of disease (NED) stage after the initial diagnosis. The primary outcome was disease-free survival and the secondary was overall survival. The Kaplan–Meier and Cox proportional hazard models were used. Results: A total of 703 patients were included. The median and maximal of follow up was 55 and 118 months, respectively. A total of 168 patients used ACE-inhibitors/ARBs, 156 patients used statins, and 81 used both. Univariate analysis showed significant reduction in breast cancer recurrence among patients who used ACE-inhibitors/ARBs (hazard ratio (HR) = 0.57; 95% CI: 0.37–0.89; p = .013) or statins (HR = 0.43; 95% CI: 0.26–0.70; p &lt; .001). After adjusting for multiple variables, the use of ACE-inhibitors/ARBs (HR = 0.49; 95% CI: 0.31–0.76; p = .002) and statins (HR = 0.40; 95% CI: 0.24–0.67; p &lt; .001) remained significant and an additive effect was found on those who used both drugs (HR = 0.30 95% CI: 0.15–0.61; p = .001). No association was found regarding overall survival. Conclusions: The use of ACE-inhibitors/ARBs, statins, and the combination of both were all associated with a reduced risk of breast cancer recurrence. This observation should prompt further exploration.&lt;/div&gt;&lt;/div&gt;Read More: http://informahealthcare.com/doi/abs/10.3109/07357907.2011.616252&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;","author":{"@type":"Person","name":"Francisco H C Felix"},"@type":"BlogPosting","url":"http://fhcflx.github.io/ciencia-medica/2011/09/24/whats-new-for-ace-inhibitors-and-cancer_24.html","headline":"What’s new for ‘ACE inhibitors and cancer’ in PubMed","dateModified":"2011-09-24T09:04:00-03:00","datePublished":"2011-09-24T09:04:00-03:00","mainEntityOfPage":{"@type":"WebPage","@id":"http://fhcflx.github.io/ciencia-medica/2011/09/24/whats-new-for-ace-inhibitors-and-cancer_24.html"},"@context":"http://schema.org"}</script>
<!-- End Jekyll SEO tag -->


  <!--
  -->
 <link rel="alternate" type="application/rss+xml" title="" href="/ciencia-medica">

  <title>What's new for 'ACE inhibitors and cancer' in PubMed</title>
  <meta name="description" content="This message contains My NCBI what's new results from the National Center for BiotechnologySender's message:  Sent on Saturday, 2011 Sep 24Search angiotensin...">

  <!-- Google Fonts loaded here depending on setting in _data/options.yml true loads font, blank does not-->
  
    <link href='//fonts.googleapis.com/css?family=Lato:400,400italic' rel='stylesheet' type='text/css'>
  

  <!-- Load up MathJax script if needed ... specify in /_data/options.yml file-->
  
    <script type="text/javascript" src="//cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
  

  <link rel="stylesheet" type="text/css" href="/ciencia-medica/css/tufte.css">
  <!-- <link rel="stylesheet" type="text/css" href="/ciencia-medica/css/print.css" media="print"> -->

  <link rel="canonical" href="http://fhcflx.github.io/ciencia-medica/2011/09/24/whats-new-for-ace-inhibitors-and-cancer_24.html">
  <link rel="icon"
        type="image/png"
        href="/assets/img/badge.png">

  <link rel="alternate" type="application/rss+xml" title="Ciência médica" href="http://fhcflx.github.io/ciencia-medica/feed.xml" />

  <link rel="apple-touch-icon" sizes="180x180" href="/ciencia-medica/apple-touch-icon.png">
  <link rel="icon" type="image/png" sizes="32x32" href="/ciencia-medica/favicon-32x32.png">
  <link rel="icon" type="image/png" sizes="16x16" href="/ciencia-medica/favicon-16x16.png">
  <link rel="manifest" href="/ciencia-medica/site.webmanifest">
  <link rel="mask-icon" href="/ciencia-medica/safari-pinned-tab.svg" color="#5bbad5">
  <link rel="shortcut icon" href="/ciencia-medica/favicon.ico">
  <meta name="msapplication-TileColor" content="#da532c">
  <meta name="msapplication-config" content="/ciencia-medica/browserconfig.xml">
  <meta name="theme-color" content="#ffffff">

</head>

  <body>
    <!--- Hader and nav template site-wide -->
<header>
    <a class="site-title" href="/ciencia-medica/"></a>
    <nav class="group">
	<a href="/ciencia-medica/"><img class="badge" src="/ciencia-medica/assets/img/mybadge.png" alt="CH"></a>
        
	
		
		    
		      <a href="/ciencia-medica/index.html">Medical Science</a>
		    
	    
  	
		
		    
		      <a href="/ciencia-medica/all-posts/index.html">All</a>
		    
	    
  	
		
		    
		      <a href="/ciencia-medica/vascular/index.html">Vascular anomalies</a>
		    
	    
  	
		
		    
		      <a href="/ciencia-medica/cancer2/index.html">Cancer</a>
		    
	    
  	
		
		    
		      <a href="/ciencia-medica/markers/index.html">Tags</a>
		    
	    
  	
		
		    
		      <a href="/ciencia-medica/about/index.html">About</a>
		    
	    
  	
        <!--<div class="trigger">
            
            
               
               <a class="page-link" href="/ciencia-medica/index.html">Medical Science</a>
               
            
               
               <a class="page-link" href="/ciencia-medica/all-posts/index.html">All</a>
               
            
               
               <a class="page-link" href="/ciencia-medica/vascular/index.html">Vascular anomalies</a>
               
            
               
               <a class="page-link" href="/ciencia-medica/cancer2/index.html">Cancer</a>
               
            
               
               <a class="page-link" href="/ciencia-medica/markers/index.html">Tags</a>
               
            
               
               <a class="page-link" href="/ciencia-medica/about/index.html">About</a>
               
            
            </div>-->
  </nav>
<div class="wrapper" style="text-align: right; line-height: 2em">
  
  

  
  
</div>
</header>

    <article class="group">
      <h1>What's new for 'ACE inhibitors and cancer' in PubMed</h1>
<p class="subtitle">

24
Setembro
  
2011</p>





<ul class="tags">
  
    <li><a href="/ciencia-medica/marcadores#Cancer" class="tag">Cancer</a></li>
  
</ul>

This message contains My NCBI what's new results from the National Center for Biotechnology<br /><b>Sender's message: </b> <br />Sent on Saturday, 2011 Sep 24<br />Search <b>angiotensin cancer</b> <br /><div><br /><br /><div><table bgcolor="#CCCCCC"><tbody><tr><td align="center">PubMed Results</td></tr></tbody></table></div><br /><div><table cellpadding="0" cellspacing="5"><tbody><tr><td nowrap="nowrap" valign="top" width="10"></td><td valign="top"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21936625" ref="ordinalpos=1">Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors,  ARBs,  and/or Statins.</a></td></tr><tr><td align="left" valign="top" width="10"><br /></td><td align="left" valign="top"><span class="jrnl" title="Cancer investigation">Cancer Invest</span>. 2011 Sep 21. [Epub ahead of print]</td></tr><tr><td align="left" valign="top" width="10"><br /></td><td align="left" valign="top">PMID: 21936625 [PubMed - as supplied by publisher]</td></tr><tr><td align="left" valign="top" width="10"><br /></td><td><div><div><div class="artAuthors"><a class="entryAuthor" href="http://informahealthcare.com/action/doSearch?action=runSearch&amp;type=advanced&amp;result=true&amp;prevSearch=%2Bauthorsfield%3A%28Chae%2C+Young+Kwang%29">Young Kwang Chae,<span class="NLM_xref-aff"><sup>1,2,</sup></span></a><a class="ref" href="http://informahealthcare.com/action/showPopup?citid=citart1&amp;id=FN0001&amp;doi=10.3109/07357907.2011.616252">§</a> <a class="entryAuthor" href="http://informahealthcare.com/action/doSearch?action=runSearch&amp;type=advanced&amp;result=true&amp;prevSearch=%2Bauthorsfield%3A%28Valsecchi%2C+Matias+E.%29">Matias E. Valsecchi,<span class="NLM_xref-aff"><sup>2,3,</sup></span></a><a class="ref" href="http://informahealthcare.com/action/showPopup?citid=citart1&amp;id=FN0001&amp;doi=10.3109/07357907.2011.616252">§</a> <a class="entryAuthor" href="http://informahealthcare.com/action/doSearch?action=runSearch&amp;type=advanced&amp;result=true&amp;prevSearch=%2Bauthorsfield%3A%28Kim%2C+Jongoh%29">Jongoh Kim,<span class="NLM_xref-aff"><sup>2,4</sup></span> </a><a class="entryAuthor" href="http://informahealthcare.com/action/doSearch?action=runSearch&amp;type=advanced&amp;result=true&amp;prevSearch=%2Bauthorsfield%3A%28Bianchi%2C+Anabella+Lucca%29">Anabella Lucca Bianchi,<span class="NLM_xref-aff"><sup>2</sup></span> </a><a class="entryAuthor" href="http://informahealthcare.com/action/doSearch?action=runSearch&amp;type=advanced&amp;result=true&amp;prevSearch=%2Bauthorsfield%3A%28Khemasuwan%2C+Danai%29">Danai Khemasuwan,<span class="NLM_xref-aff"><sup>2,5</sup></span> </a><a class="entryAuthor" href="http://informahealthcare.com/action/doSearch?action=runSearch&amp;type=advanced&amp;result=true&amp;prevSearch=%2Bauthorsfield%3A%28Desai%2C+Ajit%29">Ajit Desai,<span class="NLM_xref-aff"><sup>2</sup></span> and </a><a class="entryAuthor" href="http://informahealthcare.com/action/doSearch?action=runSearch&amp;type=advanced&amp;result=true&amp;prevSearch=%2Bauthorsfield%3A%28Tester%2C+William%29">William Tester,<span class="NLM_xref-aff"><sup>2</sup></span></a><br /><div class="fulltext"><span class="institution"><i>Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center,</i></span><i> Houston, TX,</i><span class="country"><i> USA,<sup>1</sup></i></span></div><div class="fulltext"><span class="institution"><i>Department of Medicine, Albert Einstein Medical Center,</i></span><i> Philadelphia, PA,</i> <span class="country"><i>USA,<sup>2</sup></i></span></div><div class="fulltext"><span class="institution"><i>Department of Medical Oncology, Thomas Jefferson University Hospital,</i></span><i> Philadelphia, PA, </i><span class="country"><i>USA,<sup>3</sup></i></span></div><div class="fulltext"><span class="institution"><i>Department of Medicine, Balyor College of Medicine, Houston,</i></span><i> TX,</i> <span class="country"><i>USA,<sup>4</sup></i></span></div><div class="fulltext"><span class="institution"><i>Department of Medicine, Cleveland Clinic, Cleveland,</i></span><i> OH,</i> <span class="country"><i>USA<sup>5</sup></i></span></div></div><div class="NLM_author-notes"><div class="first last"><sup>§</sup>Both the authors contributed equally to this study.</div><div class="NLM_corresp">Correspondence to: Young Kwang Chae, MD, MPH, MBA, 1515 Holcombe Blvd, Unit 463, Houston, TX 77030, <span class="country">USA</span>. email: <a class="email" href="mailto:ykchae@mdanderson.org">ykchae@mdanderson.org</a></div></div><br /><br /><div class="abstractSection"><div class="first last"><b><i>Background</i>:  Epidemiologic and biochemical evidence suggest a role of statins and  angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor  blockers (ARBs) as anti-neoplastic agents. This study was designed to  evaluate the association between the use of these agents and the risk of  breast cancer recurrence. <i>Methods</i>: We reviewed the medical  records of patients treated for stage II/III breast cancer between 1999  and 2005. Statin and ACE-inhibitors/ARB users were defined as patients  who took these medications for at least 6 months in no evidence of  disease (NED) stage after the initial diagnosis. The primary outcome was  disease-free survival and the secondary was overall survival. The  Kaplan–Meier and Cox proportional hazard models were used. <i>Results</i>:  A total of 703 patients were included. The median and maximal of follow  up was 55 and 118 months, respectively. A total of 168 patients used  ACE-inhibitors/ARBs, 156 patients used statins, and 81 used both.  Univariate analysis showed significant reduction in breast cancer  recurrence among patients who used ACE-inhibitors/ARBs (hazard ratio  (HR) = 0.57; 95% CI: 0.37–0.89; <i>p</i> = .013) or statins (HR = 0.43; 95% CI: 0.26–0.70; <i>p</i> &lt; .001). After adjusting for multiple variables, the use of ACE-inhibitors/ARBs (HR = 0.49; 95% CI: 0.31–0.76; <i>p</i> = .002) and statins (HR = 0.40; 95% CI: 0.24–0.67; <i>p</i> &lt; .001) remained significant and an additive effect was found on those who used both drugs (HR = 0.30 95% CI: 0.15–0.61; <i>p</i> = .001). No association was found regarding overall survival. <i>Conclusions</i>:  The use of ACE-inhibitors/ARBs, statins, and the combination of both  were all associated with a reduced risk of breast cancer recurrence.  This observation should prompt further exploration.</b></div></div><br />Read More: <a href="http://informahealthcare.com/doi/abs/10.3109/07357907.2011.616252">http://informahealthcare.com/doi/abs/10.3109/07357907.2011.616252</a></div></div></td></tr></tbody></table></div></div>


<article style="max-width: 90%;">
  <div id="disqus_thread"></div>
  <script>
    /**
     *  RECOMMENDED CONFIGURATION VARIABLES: EDIT AND UNCOMMENT THE SECTION BELOW TO INSERT DYNAMIC VALUES FROM YOUR PLATFORM OR CMS.
     *  LEARN WHY DEFINING THESE VARIABLES IS IMPORTANT: https://disqus.com/admin/universalcode/#configuration-variables
     */
    /*
    var disqus_config = function () {
        this.page.url = PAGE_URL;  // Replace PAGE_URL with your page's canonical URL variable
        this.page.identifier = PAGE_IDENTIFIER; // Replace PAGE_IDENTIFIER with your page's unique identifier variable
    };
    */
      (function() {  // DON'T EDIT BELOW THIS LINE
          var d = document, s = d.createElement('script');
              s.src = '//pharmak-on.disqus.com/embed.js';

            s.setAttribute('data-timestamp', +new Date());
            (d.head || d.body).appendChild(s);
        })();
  </script>
  <noscript>Please enable JavaScript to view the <a href="https://disqus.com/?ref_noscript" rel="nofollow">comments powered by Disqus.</a></noscript>
</article>


    </article>
    <span class="print-footer">What's new for 'ACE inhibitors and cancer' in PubMed - September 24, 2011 - fhcflx</span>
    <footer>
  <hr class="slender">
  <ul class="footer-links">
    <li><a href="mailto:fhcflx@outlook.com"><span class="icon-mail"></span></a></li>
    
      <li>
        <a href="//www.twitter.com/fhcflx"><span class="icon-twitter"></span></a>
      </li>
    
      <li>
        <a href="//plus.google.com/+FranciscoHCFelix"><span class="icon-googleplus"></span></a>
      </li>
    
      <li>
        <a href="//github.com/fhcflx/ciencia-medica"><span class="icon-github"></span></a>
      </li>
    
      <li>
        <a href="//www.flickr.com/photos/fhcflx"><span class="icon-flickr"></span></a>
      </li>
    
      <li>
        <a href=""><span class="icon-feed"></span></a>
      </li>
    
    <li><a href=https://travis-ci.org/fhcflx/ciencia-medica ><img alt='travis-ci build' src=https://img.shields.io/travis/fhcflx/ciencia-medica.svg?colorA=a00000&colorB=a00000></a></li>
  </ul>
<div class="credits">
<span>&copy; 2019 &nbsp;&nbsp;FHCFLX</span></br> <br>
<span>Este sítio foi criado com o <a href="//github.com/clayh53/tufte-jekyll">tema Tufte para Ciência médica </a> no <a href="//jekyllrb.com">Jekyll</a>.</span>
</div>
</footer>

  </body>
</html>
